Logo image of THAR

THARIMMUNE INC (THAR) Stock Fundamental Analysis

NASDAQ:THAR - Nasdaq - US4327053090 - Common Stock - Currency: USD

1.51  +0.02 (+1.34%)

After market: 1.48 -0.03 (-1.99%)

Fundamental Rating

2

Overall THAR gets a fundamental rating of 2 out of 10. We evaluated THAR against 562 industry peers in the Biotechnology industry. THAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. THAR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year THAR has reported negative net income.
THAR had a negative operating cash flow in the past year.
In the past 5 years THAR always reported negative net income.
THAR had a negative operating cash flow in each of the past 5 years.
THAR Yearly Net Income VS EBIT VS OCF VS FCFTHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

THAR has a Return On Assets of -327.75%. This is amonst the worse of the industry: THAR underperforms 95.21% of its industry peers.
THAR's Return On Equity of -932.83% is on the low side compared to the rest of the industry. THAR is outperformed by 82.98% of its industry peers.
Industry RankSector Rank
ROA -327.75%
ROE -932.83%
ROIC N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THAR Yearly ROA, ROE, ROICTHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for THAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THAR Yearly Profit, Operating, Gross MarginsTHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for THAR has been increased compared to 1 year ago.
The number of shares outstanding for THAR has been increased compared to 5 years ago.
THAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
THAR Yearly Shares OutstandingTHAR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
THAR Yearly Total Debt VS Total AssetsTHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

THAR has an Altman-Z score of -23.69. This is a bad value and indicates that THAR is not financially healthy and even has some risk of bankruptcy.
THAR's Altman-Z score of -23.69 is on the low side compared to the rest of the industry. THAR is outperformed by 89.18% of its industry peers.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.69
ROIC/WACCN/A
WACCN/A
THAR Yearly LT Debt VS Equity VS FCFTHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.54 indicates that THAR should not have too much problems paying its short term obligations.
THAR has a worse Current ratio (1.54) than 81.56% of its industry peers.
A Quick Ratio of 1.54 indicates that THAR should not have too much problems paying its short term obligations.
The Quick ratio of THAR (1.54) is worse than 80.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
THAR Yearly Current Assets VS Current LiabilitesTHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.96% over the past year.
EPS 1Y (TTM)94.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

THAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.09% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THAR Yearly EPS VS EstimatesTHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

THAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THAR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THAR Price Earnings VS Forward Price EarningsTHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THAR Per share dataTHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

THAR's earnings are expected to grow with 41.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.09%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

THAR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THARIMMUNE INC

NASDAQ:THAR (5/9/2025, 8:24:09 PM)

After market: 1.48 -0.03 (-1.99%)

1.51

+0.02 (+1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)N/A N/A
Inst Owners8.07%
Inst Owner Change0.3%
Ins Owners1.48%
Ins Owner Change33.93%
Market Cap3.19M
Analysts82.86
Price Target5.1 (237.75%)
Short Float %3.54%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.44
P/tB 2.44
EV/EBITDA N/A
EPS(TTM)-9.89
EYN/A
EPS(NY)-7.2
Fwd EYN/A
FCF(TTM)-5.17
FCFYN/A
OCF(TTM)-5.17
OCFYN/A
SpS0
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -327.75%
ROE -932.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -23.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.34%
OCF growth 3YN/A
OCF growth 5YN/A